Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.

doi:10.1111/liv.14797

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.

Liver international : official journal of the International Association for the Study of the Liver - 1 Aug 2021

Di Maio Velia Chiara, Barbaliscia Silvia, Teti Elisabetta, Fiorentino Gianluca, Milana Martina, Paolucci Stefania, Pollicino Teresa, Morsica Giulia, Starace Mario, Bruzzone Bianca, Gennari William, Micheli Valeria, Yu La Rosa Katia, Foroghi Luca, Calvaruso Vincenza, Lenci Ilaria, Polilli Ennio, Babudieri Sergio, Aghemo Alessio, Raimondo Giovanni, Sarmati Loredana, Coppola Nicola, Pasquazzi Caterina, Baldanti Fausto, Parruti Giustino, Perno Carlo Federico, Angelico Mario, Craxì Antonio, Andreoni Massimo, Ceccherini-Silberstein Francesca

Abstract excerpt

AIM: This study aimed to investigate the role of resistance-associated substitutions (RASs) to direct-acting-antivirals (DAAs) in HCV genotype 3 (GT3). METHODS: Within the Italian VIRONET-C network, a total of 539 GT3-infected patients (417 DAA-naïve and 135 DAA-failures, of them, 13 at both baseline and failure) were analysed. Sanger sequencing of NS3/NS5A/NS5B was performed following home-made protocols....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Italy

Share to Sofosbuvir

Share to Sustained Virologic Response

Share to Viral Nonstructural Proteins

Source

Open in PubMed

Identifiers

PMID: 33497016
DOI: 10.1111/liv.14797

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.PMID 33497016Read ↗

Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.Semantic proximity Read ↗

Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.Semantic proximity Read ↗

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.Semantic proximity Read ↗

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.Semantic proximity Read ↗

HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.Semantic proximity Read ↗

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.Semantic proximity Read ↗

Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitorsSemantic proximity Read ↗

Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure.Semantic proximity Read ↗

Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.Semantic proximity Read ↗

Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.Semantic proximity Read ↗

Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in BrazilSemantic proximity Read ↗

Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.